(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

Inclusion Criteria:

• Patients fulfilling the following criteria are eligible for participation in thestudy:

• Male and female patients, 18-75 years old, who are able to understand andvoluntarily provide written informed consent.

• Patients in UCDAI remission defined as a UCDAI score ≤ 1 point with a score of 0for rectal bleeding and stool frequency, and a ≥ 1 point reduction from baselinein the endoscopy score without any sign of mucosal friability (score 0 formucosal appearance).

• Patients who have completed all End of Study assessments for the CB-01-02/01,CB-01-02/02 and CB-01-02/06 studies.

• Females of child-bearing potential must have had a serum pregnancy test performedat the End of Study visit of the parent studies and must use an acceptablecontraceptive method throughout the study treatment period.

Exclusion Criteria:

• Patients who meet any of the following criteria at screening visit are to be excludedfrom study participation:

• Subjects who have withdrawn from studies CB-01-02/01, CB 01 02/02 or CB-01-02/06.

• Subjects who did not achieve induction of remission according to the primaryendpoint definition in studies CB-01-02/01, CB 01 02/02 or CB-01-02/06 (i.e.clinical remission defined as a UCDAI score ≤ 1 point with a score of 0 forrectal bleeding and stool frequency, and ≥ 1 point reduction from baseline in theendoscopy score without any sign of mucosal friability [score 0 for mucosalappearance]).

• Subjects with bone density lower than normal by age and sex (T-score lower than -1) as assessed via dual energy X-ray absorptiometry (DXA) scans.